
How would you like to read? Click one below.
At any time, click this
to change word size.

Disclaimer
By selecting this link, you will be leaving www.LUCENTIS.com and going to a site that is not controlled by or affiliated with Genentech USA, Inc. Genentech is neither affiliated with nor endorses any of the aforementioned organizations. The information provided by Genentech or these organizations is meant for informational purposes only and is not meant to replace your doctor's medical advice.

Disclaimer
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
Who is LUCENTIS for?
LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (wAMD).
What important safety information should I know about LUCENTIS?
LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious infections inside the eye. You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients.
Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes.
Some patients have had increased eye pressure before and within 1 hour of an injection.
Serious side effects include inflammation inside the eye and, rarely, problems related to the injection procedure, such as cataracts. These side effects can make your vision worse.
The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, headache, joint pain, and lung/airway infections.
If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away.
For additional safety information, please talk to your doctor and see the LUCENTIS full prescribing information.

Joan A.'s Story
Who is LUCENTIS for?
LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (wAMD).
What important safety information should I know about LUCENTIS?
LUCENTIS is a prescription medication given by injection into the eye, and it has side effects. Some LUCENTIS patients have had detached retinas and serious infections inside the eye. You should not use LUCENTIS if you have an infection in or around the eye or are allergic to LUCENTIS or any of its ingredients.
Uncommonly, LUCENTIS patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes.
Some patients have had increased eye pressure before and within 1 hour of an injection.
Serious side effects include inflammation inside the eye and, rarely, problems related to the injection procedure, such as cataracts. These side effects can make your vision worse.
The most common eye-related side effects are increased redness in the white of the eye, eye pain, small specks in vision, and increased eye pressure. The most common non–eye-related side effects are nose and throat infections, headache, joint pain, and lung/airway infections.
If your eye becomes red, sensitive to light, or painful, or if you have a change in vision, call or visit your eye doctor right away.
For additional safety information, please talk to your doctor and see the LUCENTIS full prescribing information.
This site is intended for US residents only.








After John retired, I urged him to start looking after his health. At the time, I was an office manager for a prominent physician and naturally health-conscious. So John started making the rounds of regular physicals, dental appointments, and exercising. In the summer of 2004, he visited an ophthalmologist for a complete eye exam. At the conclusion of the exam, the doctor informed John that he had dry AMD, in both eyes. And there were no symptoms. In a matter of months, he developed wet AMD in his left eye. His right eye was still okay. Suffice it to say, we were very concerned about his future, and we tried to learn as much as we could about scientific advances being made in the control and eventual cure of wet AMD.